Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2020-01-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
独立董事关于控股子公司山东凯盛新材料股份有限公司修订股票期权激励计划的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of a company regarding the revision of a stock option incentive plan of its controlling subsidiary. It references compliance with laws and regulations and expresses agreement with the plan revision. The document is short (432 characters) and does not contain financial statements or detailed financial data. It is a formal opinion or certification related to governance and compliance rather than a full report or announcement of financial results. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement or a regulatory filing in the sense of officer certification. The closest fitting category is Regulatory Filings (RNS) as a general compliance-related announcement that does not fit other specific categories.
2020-01-20 Chinese
第七届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 13th meeting of the 7th Board of Directors of Huabang Life Health Co., Ltd. It details the meeting date, voting results, and mentions related announcements published elsewhere. The document does not contain financial statements or detailed management discussion but rather reports on board decisions and approvals, including a stock option incentive plan revision and the 2020 budget report. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short and it is not a full report or financial statement, so it is not an Annual Report or Interim Report. Therefore, the classification is MANG with high confidence.
2020-01-20 Chinese
关于控股子公司山东凯盛新材料股份有限公司修订股票期权激励计划的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Huabang Life Health Co., Ltd. regarding the revision of the stock option incentive plan of its controlling subsidiary, Shandong Kaisheng New Materials Co., Ltd. It details the changes to the incentive plan, including adjustments to the vesting periods and cancellation of the third exercise period. The document includes meeting dates, resolutions, and independent directors' opinions on the legality and compliance of the plan revision. There are no financial statements or comprehensive financial data presented, nor is this a full report like an annual or interim report. The document is a formal announcement about a management-related plan change, specifically concerning stock option incentives, which falls under management or board information about company governance and internal plans. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 2153 characters, which is relatively short but contains substantive content about management decisions rather than just a notice or report publication announcement.
2020-01-20 Chinese
关于全资子公司获得《药品注册批件》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary obtaining a drug registration approval from the National Medical Products Administration (国家药品监督管理局). It details the drug name, specifications, registration number, and the impact on the company. The document is short (1171 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category about company operations and approvals, which aligns with Regulatory Filings (RNS).
2020-01-07 Chinese
关于全资子公司获得《药品注册批件》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its wholly-owned subsidiary obtaining a drug registration approval from the National Medical Products Administration. It describes the drug details, impact on the company, and risk warnings. The document is short (1003 characters) and is an announcement of a regulatory approval event, not a financial report or detailed filing. It does not contain financial statements, management discussion, or regulatory certifications. It is not an earnings release, annual report, or any detailed financial or governance report. The content fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about a business development that does not fit other specific categories.
2019-12-30 Chinese
2019年第三次临时股东大会的法律意见书
Regulatory Filings
2019-12-30 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.